Literature DB >> 17928226

Arm morbidity following sentinel lymph node biopsy or axillary lymph node dissection: a study from the Danish Breast Cancer Cooperative Group.

Anders Husted Madsen1, Karen Haugaard, Jan Soerensen, Susanne Bokmand, Esbern Friis, Helle Holtveg, Jens Peter Garne, John Horby, Peer Christiansen.   

Abstract

BACKGROUND: Sentinel lymph node biopsy was implemented in the treatment of early breast cancer with the aim of reducing shoulder and arm morbidity. Relatively few prospective studies have been published where the morbidity was assessed by clinical examination. Very few studies have examined the impact on shoulder mobility of node positive patients having a secondary axillary dissection because of the findings of metastases postoperatively. AIM: We aimed to investigate the objective and subjective arm morbidity in node negative and node positive patients. METHODS AND MATERIALS: In a prospective study, 395 patients with tumors less than 4 cm, were included. Patients were recruited from seven Danish breast cancer clinics. Both subjective and objective arm and shoulder morbidity were measured before, 6 and 18 months after the operation.
RESULTS: Comparing node negative patients having a sentinel lymph node biopsy with node negative patients having a lymph node dissection of levels I and II of the axilla, we found significant increase in arm volume among the patients who had an axillary dissection. Only minor, but significant, differences in shoulder mobility were observed comparing the two groups of node negative patients. Highly significant difference was found comparing sensibility. Comparing the morbidity in node positive patients who had a one-step axillary dissection with patients having a two-step procedure (sentinel lymph node biopsy followed by delayed axillary dissection) revealed no difference in objective or subjective arm morbidity.
CONCLUSION: Node negative patients operated with sentinel lymph node biopsy have less arm morbidity compared with node negative patients operated with axillary lymph node dissection. Node positive patients who had a secondary axillary lymph node dissection after sentinel lymph node biopsy had no difference in either objective or subjective morbidity compared with node positive patients having a one-step axillary dissection.

Entities:  

Mesh:

Year:  2007        PMID: 17928226     DOI: 10.1016/j.breast.2007.08.006

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  16 in total

1.  Risk factors for lymphedema in a prospective breast cancer survivorship study: the Pathways Study.

Authors:  Marilyn L Kwan; Jeanne Darbinian; Kathryn H Schmitz; Rebecca Citron; Paula Partee; Susan E Kutner; Lawrence H Kushi
Journal:  Arch Surg       Date:  2010-11

2.  Return to work in low-income Latina and non-Latina white breast cancer survivors: a 3-year longitudinal study.

Authors:  Victoria S Blinder; Sujata Patil; Amardeep Thind; Allison Diamant; Clifford A Hudis; Ethan Basch; Rose C Maly
Journal:  Cancer       Date:  2011-08-25       Impact factor: 6.860

3.  Patient-reported outcomes in sentinel node-negative adjuvant breast cancer patients receiving sentinel-node biopsy or axillary dissection: National Surgical Adjuvant Breast and Bowel Project phase III protocol B-32.

Authors:  Stephanie R Land; Jacek A Kopec; Thomas B Julian; Ann M Brown; Stewart J Anderson; David N Krag; Nicholas J Christian; Joseph P Costantino; Norman Wolmark; Patricia A Ganz
Journal:  J Clin Oncol       Date:  2010-08-02       Impact factor: 44.544

4.  Comparison of mastoscopic and conventional axillary lymph node dissection in breast cancer: long-term results from a randomized, multicenter trial.

Authors:  Chengyu Luo; Wenbin Guo; Jie Yang; Qiuru Sun; Wei Wei; Suhua Wu; Shubing Fang; Qingliang Zeng; Zhensheng Zhao; Fanjie Meng; Xuandong Huang; Xianlan Zhang; Ruihua Li; Xiufeng Ma; Chaoying Luo; Yun Yang
Journal:  Mayo Clin Proc       Date:  2012-11-09       Impact factor: 7.616

5.  A longitudinal comparison of arm morbidity in stage I-II breast cancer patients treated with sentinel lymph node biopsy, sentinel lymph node biopsy followed by completion lymph node dissection, or axillary lymph node dissection.

Authors:  Jan J Kootstra; Josette E H M Hoekstra-Weebers; Johan S Rietman; Jakob de Vries; Peter C Baas; Jan H B Geertzen; Harald J Hoekstra
Journal:  Ann Surg Oncol       Date:  2010-03-11       Impact factor: 5.344

6.  Relationship between arm morbidity and patient-reported outcomes following surgery in women with node-negative breast cancer: NSABP protocol B-32.

Authors:  Jacek A Kopec; Linda H Colangelo; Stephanie R Land; Thomas B Julian; Ann M Brown; Stewart J Anderson; David N Krag; Takamaru Ashikaga; Joseph P Costatino; Norman Wolmark; Patricia A Ganz
Journal:  J Support Oncol       Date:  2013-03

Review 7.  Persistent Post-Mastectomy Pain: Risk Factors and Current Approaches to Treatment.

Authors:  Raymond C Tait; Kim Zoberi; McKenzie Ferguson; Kimberly Levenhagen; Rebecca A Luebbert; Kevin Rowland; Gretchen B Salsich; Christopher Herndon
Journal:  J Pain       Date:  2018-06-30       Impact factor: 5.820

8.  Cytokeratin on frozen sections of sentinel node may spare breast cancer patients secondary axillary surgery.

Authors:  Elisabeth Specht Stovgaard; Tove Filtenborg Tvedskov; Anne Vibeke Lænkholm; Eva Balslev
Journal:  Patholog Res Int       Date:  2012-05-09

9.  Breast cancer: from "maximum tolerable" to "minimum effective" treatment.

Authors:  Umberto Veronesi; Vaia Stafyla; Alberto Luini; Paolo Veronesi
Journal:  Front Oncol       Date:  2012-10-08       Impact factor: 6.244

10.  Early contralateral shoulder-arm morbidity in breast cancer patients enrolled in a randomized trial of post-surgery radiation therapy.

Authors:  Nele Adriaenssens; Vincent Vinh-Hung; Geertje Miedema; Harijati Versmessen; Jan Lamote; Marian Vanhoeij; Pierre Lievens; Hilde van Parijs; Guy Storme; Mia Voordeckers; Mark De Ridder
Journal:  Breast Cancer (Auckl)       Date:  2012-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.